BridgeBio Oncology
BBOT
52 hedge funds and large institutions have $725M invested in BridgeBio Oncology in 2025 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 12 increasing their positions, 12 reducing their positions, and 4 closing their positions.
250% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 4
24% more funds holding
Funds holding: 42 → 52 (+10)
10% more capital invested
Capital invested by funds: $658M → $725M (+$67.2M)
0.65% more ownership
Funds ownership: 71.74% → 72.38% (+0.65%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$7.12M |
| 2 |
LCM
Laurion Capital Management
New York
|
+$5.08M |
| 3 |
PBA
Paradigm Biocapital Advisors
New York
|
+$4.79M |
| 4 |
HS
HighVista Strategies
Boston,
Massachusetts
|
+$2.78M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$5.3M |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$3.33M |
| 3 |
Millennium Management
New York
|
-$1.55M |
| 4 |
SC
Stempoint Capital
New York
|
-$1.21M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.06M |
BBOT Hedge Fund Activity: Q4 2025 in Review
52 of the 8,281 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Oncology (BBOT) for Q4 2025, worth a combined $725M — up 10% from $658M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new BBOT positions and 4 closed out — a net gain of 10 holders — while 12 added to existing stakes and 12 trimmed.
The largest buyer was Armistice Capital, adding an estimated $7.12M. The largest seller was Silverarc Capital Management, exiting entirely with an estimated $5.3M sold.
- 52 institutional investors held BridgeBio Oncology (BBOT) as of Q4 2025, up from 42 in Q3 2025.
- Funds reported $725M of BridgeBio Oncology stock for Q4 2025, up 10% quarter-over-quarter.
- 14 funds opened new BridgeBio Oncology positions in Q4 2025 and 4 closed out, a net change of +10 holders.
- The largest BridgeBio Oncology buyer in Q4 2025 was Armistice Capital, an estimated $7.12M added.
- The largest BridgeBio Oncology seller in Q4 2025 was Silverarc Capital Management, an estimated $5.3M sold.
Based on aggregated 13F filings for Q4 2025.